Swiss National Bank Sells 1,300 Shares of Zoetis Inc. (NYSE:ZTS)

Swiss National Bank lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,354,332 shares of the company’s stock after selling 1,300 shares during the period. Swiss National Bank’s holdings in Zoetis were worth $264,609,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Intech Investment Management LLC boosted its holdings in Zoetis by 94.6% during the first quarter. Intech Investment Management LLC now owns 2,320 shares of the company’s stock worth $393,000 after buying an additional 1,128 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Zoetis by 49.6% during the 1st quarter. Acadian Asset Management LLC now owns 25,051 shares of the company’s stock valued at $4,235,000 after purchasing an additional 8,302 shares in the last quarter. Jacobi Capital Management LLC lifted its holdings in shares of Zoetis by 1.5% during the 1st quarter. Jacobi Capital Management LLC now owns 8,161 shares of the company’s stock valued at $1,381,000 after purchasing an additional 121 shares in the last quarter. Catalytic Wealth RIA LLC lifted its holdings in shares of Zoetis by 7.5% during the 1st quarter. Catalytic Wealth RIA LLC now owns 4,107 shares of the company’s stock valued at $695,000 after purchasing an additional 285 shares in the last quarter. Finally, Beaumont Financial Advisors LLC raised its position in Zoetis by 31.1% in the 1st quarter. Beaumont Financial Advisors LLC now owns 1,855 shares of the company’s stock valued at $314,000 after buying an additional 440 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $175.14 on Friday. The stock has a fifty day moving average price of $187.09 and a 200-day moving average price of $180.23. The company has a market cap of $79.02 billion, a price-to-earnings ratio of 32.92, a PEG ratio of 2.69 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.36 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.99%. Zoetis’s payout ratio is 32.52%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ZTS. Stifel Nicolaus lifted their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. BTIG Research boosted their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. boosted their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Piper Sandler boosted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.